The Penicillin Allergy Decision Rule—Something New for Penicillin Allergy

Ramsey, Allison; Mustafa, S. Shahzad

doi:10.1001/jamainternmed.2023.3936

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Published studies exploring the management of PAL patients are increasing ( Trubiano et al, 2016 ; Trubiano et al, 2017a ; Trubiano et al, 2017b ; Rose et al, 2020 ; Wijnakker et al, 2023 ; Stone et al, 2020 ; Ramsey and Mustafa, 2023 ). Early de-labelling of PAL patients is strongly supported as one of the main actions in Antimicrobial Stewardship Programs (ASP) to avoid unnecessary use of broad-spectrum antibiotics in low-risk allergic patients and to promote the administration of first-line treatment at an early stage of infection ( Wijnakker et al, 2023 ; Ramsey and Mustafa, 2023 ). There are some strategies available to remove an allergy label, such as skin tests and oral provocation, as well as obtaining a complete allergy history ( Trubiano et al, 2016 ; Trubiano et al, 2017a ; Trubiano et al, 2017b ; Rose et al, 2020 ; Stone et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A retrospective case-control study to evaluate the use of beta-lactam desensitization in the management of penicillin-allergic patients: a potential strategy for Antimicrobial Stewardship Programs

Rodríguez-Alarcón,

Sanz de Mena,

Alanti

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: Penicillin allergy labels (PAL) are common in the hospital setting and are associated with worse clinical outcomes. Desensitization can be a useful strategy for allergic patients when alternative options are suboptimal or not available. The aim was to compare clinical outcomes of patients with PAL managed with antibiotic desensitization vs. those who received alternative non-beta-lactam antibiotic treatments.Methods: A retrospective 3:1 case-control study was performed between 2015–2022. Cases were adult PAL patients with infection who required antibiotic desensitization; controls were PAL patients with infection managed with an alternative antibiotic treatment. Cases and controls were adjusted for age, sex, infection source, and critical or non-critical medical services.Results: Fifty-six patients were included: 14 in the desensitization group, 42 in the control group. Compared to the control group, desensitized PAL patients had more comorbidities, with a higher Charlson index (7.4 vs. 5; p = 0.00) and more infections caused by multidrug-resistant (MDR) pathogens (57.1% vs. 28.6%; p = 0.05). Thirty-day mortality was 14.3% in the desensitized group, 28.6% in the control group (p = 0.24). Clinical cure occurred in 71.4% cases and 54.8% controls (p = 0.22). Four control patients selected for MDR strains after alternative treatment; selection of MDR strains did not occur in desensitized patients. Five controls had antibiotic-related adverse events, including Clostridioides difficile or nephrotoxicity. No antibiotic-related adverse events were found in the study group. In multivariate analysis, no differences between groups were observed for main variables.Conclusion: Desensitization was not associated with worse clinical outcomes, despite more severe patients in this group. Our study suggests that antibiotic desensitization may be a useful Antimicrobial Stewardship tool for the management of selected PAL patients.

show abstract